pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,145 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1888Endpoints1464Fierce Biotech779BioSpace767BioPharma Dive553raps253onclive165fda recalls
therapy area
allOncology13068Rare Disease3378Immunology3067Cardiology2865Hematology2334Pulmonology2285Vaccines
  • Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancer
    Merck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…
    Endpoints · 1h agoPositive readoutPositive↗ source
  • China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slump
    Biotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
    BioPharma Dive · 5h agoDealNeutral↗ source
← prev
page 1 of 126
next →
122
fda medwatch116
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filing
    Celldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
    BioPharma Dive · 4h agoNegative readoutNegative↗ source
  • Celldex drops eczema antibody barzolvolimab after Phase 2 failure
    Celldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…
    Endpoints · 4h agoNegative readoutNegative↗ source
  • FDA delays decision on Belite Bio's Stargardt disease drug to May 12
    The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
    Fierce Biotech · 8h agoRegulatoryNeutral↗ source
  • Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitis
    Both Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
    Fierce Biotech · 13h agoNegative readoutNegative↗ source
  • Teva appoints interim R&D head as Eric Hughes departs
    Teva announced that its global research and development leader and chief medical officer, Eric Hughes, has left the company. Hughes, who joined Teva in 2022 after a senior role at Vertex, will be s…
    Endpoints · 5h agoNeutral↗ source
  • CNS players discuss deals, psychiatry challenges and Alzheimer focus at Jefferies London conference
    The Jefferies Global Healthcare conference in London brought together several companies active in the central nervous system and psychiatry sectors. Attendees heard updates from a range of drugmake…
    Endpoints · 5h agoNeutral↗ source
  • ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loom
    As the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.
    Fierce Biotech · 10h agoNeutral↗ source
  • Pharma layoffs continue in New Jersey; Bausch + Lomb drug misses endpoint
    Plus news about GSK, BioVersys, United Therapeutics and Savara. New Jersey pharma layoffs continue: Novo will lay off 215 workers in Plainsboro, taking effect in February 2027, according to a November
    Endpoints · 34m ago↗ source
  • KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach
    Revolution Medicines posted strong data on its targeted pancreatic cancer drug Thursday evening, but competition is building at every turn in the KRAS field. RevMed’s game-changing pan-RAS drug Ras…
    Endpoints · 50m ago↗ source
  • Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
    Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
    Fierce Biotech · 9h ago↗ source
  • US panel warns China’s biotech plan could dominate sector and threaten drug supply chain
    A congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…
    BioPharma Dive · 1d agoRegulatoryNegative↗ source
  • Novartis CEO says AI could cut drug development time and boost success rates
    At an investor event in London, Novartis chief executive Vas Narasimhan, who also sits on the board of AI company Anthropic, explained how the Swiss drugmaker is turning to artificial intelligence…
    Fierce Biotech · 1d agoPositive↗ source
  • FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravis
    The Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
    BioPharma Dive · 1d agoApprovalPositive↗ source
  • Congressional biotech panel cautions on rising China licensing deals
    A bipartisan congressional commission that advises on U.S. biotech competitiveness is concluding its work with a focus on partnerships with Chinese firms. The panel highlighted the growing number…
    Endpoints · 21h agoRegulatoryNegative↗ source
  • Sanofi's Infilbray receives first U.S. approval for treating neurological symptoms of Gaucher disease
    Sanofi announced that the U.S. Food and Drug Administration has granted approval for Infilbray, a therapy aimed at the neurological manifestations of Gaucher disease, a rare genetic disorder. The…
    Endpoints · 21h agoApprovalPositive↗ source
  • Sanofi explores acquisition of Insmed in potential major biopharma deal
    Sanofi is reportedly evaluating a purchase of the U.S. drugmaker Insmed, according to a Bloomberg News report. The potential transaction would rank among the largest biopharma acquisitions in rece…
    Endpoints · 1d agoDealNeutral↗ source
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 1d agoApprovalPositive↗ source
  • Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding round
    Isomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
    Fierce Biotech · 1d agoDealPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 1d agoDealPositive↗ source
  • Novartis CEO says shareholders remain supportive despite recent trial setbacks
    Novartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
    Fierce Biotech · 1d agoPositive↗ source
  • Sanofi receives FDA clearance for Infilbray, first pill to treat neurological symptoms of Type 3 Gaucher disease
    Sanofi received FDA clearance for Infilbray, a once-daily pill for Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. The drug, inherited from Sanofi’s 2011 acquisition…
    BioPharma Dive · 23h agoApprovalPositive↗ source
  • Eli Lilly breaks ground on $3.5 billion Pennsylvania plant to produce obesity drugs
    Eli Lilly has begun construction of a new manufacturing facility in the Lehigh Valley region of Pennsylvania. The $3.5 billion plant is slated to increase capacity for the company’s obesity drug po…
    Endpoints · 1d agoNeutral↗ source
  • Chinese AI lab MegaRobo secures almost $200 million in funding as Isomorphic strikes partnership with Merck
    Chinese AI and lab-automation company MegaRobo announced it has raised close to $200 million, according to a post on WeChat. The capital injection is intended to expand the firm’s artificial-intel…
    Endpoints · 1d agoDealPositive↗ source